Summary | |
---|---|
Symbol | KIR2DS2 |
Name | killer cell immunoglobulin-like receptor, two domains, short cytoplasmic tail, 2 |
Aliases | cl-49; nkat5; 183ActI; CD158J; NKAT-5; CD158 antigen-like family member J; NK receptor 183 ActI; killer-cell ...... |
Chromosomal Location | 19q13.4 alternate reference locus |
External Links | HGNC, NCBI, Ensembl, Uniprot, GeneCards |
Content |
Basic function annotation. > Subcellular Location, Domain and Function > Gene Ontology > KEGG and Reactome Pathway |
Subcellular Location | Cell membrane; Single-pass type I membrane protein. |
Domain |
PF00047 Immunoglobulin domain |
Function |
Receptor on natural killer (NK) cells for HLA-C alleles. Does not inhibit the activity of NK cells. |
Biological Process | - |
Molecular Function | - |
Cellular Component | - |
KEGG |
hsa04612 Antigen processing and presentation hsa04650 Natural killer cell mediated cytotoxicity |
Reactome |
R-HSA-1280218: Adaptive Immune System R-HSA-2172127: DAP12 interactions R-HSA-168256: Immune System R-HSA-198933: Immunoregulatory interactions between a Lymphoid and a non-Lymphoid cell R-HSA-168249: Innate Immune System |
Summary | |
---|---|
Symbol | KIR2DS2 |
Name | killer cell immunoglobulin-like receptor, two domains, short cytoplasmic tail, 2 |
Aliases | cl-49; nkat5; 183ActI; CD158J; NKAT-5; CD158 antigen-like family member J; NK receptor 183 ActI; killer-cell ...... |
Chromosomal Location | 19q13.4 alternate reference locus |
External Links | HGNC, NCBI, Ensembl, Uniprot, GeneCards |
Content | Literatures that report relations between KIR2DS2 and anti-tumor immunity. The specific mechanism were also collected if the literature reports that a gene specifically promotes or inhibits the infiltration or function of T/NK cells. |
Literatures describing the relation between KIR2DS2 and anti-tumor immunity in human cancer.
|
Summary | |
---|---|
Symbol | KIR2DS2 |
Name | killer cell immunoglobulin-like receptor, two domains, short cytoplasmic tail, 2 |
Aliases | cl-49; nkat5; 183ActI; CD158J; NKAT-5; CD158 antigen-like family member J; NK receptor 183 ActI; killer-cell ...... |
Chromosomal Location | 19q13.4 alternate reference locus |
External Links | HGNC, NCBI, Ensembl, Uniprot, GeneCards |
Content | High-throughput screening data (e.g. CRISPR-Cas9, shRNA and RNAi) for T cell-mediated killing. Genetic screen techniques can identify mechanisms of tumor cell resistance (e.g., PTPN2) and sensitivity (e.g., APLNR) to killing by cytotoxic T cells, the central effectors of anti-tumor immunity. After comprehensively searching, eight groups of screening data sets were collected in the current database. In this tab, users can check whether their selected genes cause resistance or increase sensitivity to T cell-mediated killing in various data sets. |
> High-throughput Screening
[ TOP ]
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Statistical results of KIR2DS2 in screening data sets for detecting immune reponses.
|
Summary | |
---|---|
Symbol | KIR2DS2 |
Name | killer cell immunoglobulin-like receptor, two domains, short cytoplasmic tail, 2 |
Aliases | cl-49; nkat5; 183ActI; CD158J; NKAT-5; CD158 antigen-like family member J; NK receptor 183 ActI; killer-cell ...... |
Chromosomal Location | 19q13.4 alternate reference locus |
External Links | HGNC, NCBI, Ensembl, Uniprot, GeneCards |
Content |
Transcriptomic and genomic profiling of pre-treated tumor biopsies from responders and non-responders to immunotherapy. These data were used to identify signatures and mechanisms of response to checkpoint blockade (e.g., anti-PDL1 and anti-PD1). One example is that mutations in the gene PBRM1 benefit clinical survival of patients with clear cell renal cell carcinoma. After comprehensively searching, we collected 5 and 6 of transcriptomic and genomic data sets, respectively. In this tab, users can check whether their selected genes have significant difference of expression or mutation between responders and non-responders in various data sets. > Expression difference between responders and non-responders > Mutation difference between responders and non-responders |
Points in the above scatter plot represent the expression difference of KIR2DS2 in various data sets.
|
There is no record. |
Summary | |
---|---|
Symbol | KIR2DS2 |
Name | killer cell immunoglobulin-like receptor, two domains, short cytoplasmic tail, 2 |
Aliases | cl-49; nkat5; 183ActI; CD158J; NKAT-5; CD158 antigen-like family member J; NK receptor 183 ActI; killer-cell ...... |
Chromosomal Location | 19q13.4 alternate reference locus |
External Links | HGNC, NCBI, Ensembl, Uniprot, GeneCards |
Content |
Relations between abundance of tumor-infiltrating lymphocytes (TILs) and expression, copy number, methylation, or mutation of KIR2DS2. The immune-related signatures of 28 TIL types from Charoentong's study, which can be viewed in the download page. For each cancer type, the relative abundance of TILs were inferred by using gene set variation analysis (GSVA) based on gene expression profile. In this tab, users can examine which kinds of TILs might be regulated by the current gene. |
Summary | |
---|---|
Symbol | KIR2DS2 |
Name | killer cell immunoglobulin-like receptor, two domains, short cytoplasmic tail, 2 |
Aliases | cl-49; nkat5; 183ActI; CD158J; NKAT-5; CD158 antigen-like family member J; NK receptor 183 ActI; killer-cell ...... |
Chromosomal Location | 19q13.4 alternate reference locus |
External Links | HGNC, NCBI, Ensembl, Uniprot, GeneCards |
Content |
Relations between three kinds of immunomodulators and expression, copy number, methylation, or mutation of KIR2DS2. These immunomo-dulators were collected from Charoentong's study. In this tab, users can examine which immunomodulators might be regulated by KIR2DS2. > Immunoinhibitor > Immunostimulator > MHC molecule |
Summary | |
---|---|
Symbol | KIR2DS2 |
Name | killer cell immunoglobulin-like receptor, two domains, short cytoplasmic tail, 2 |
Aliases | cl-49; nkat5; 183ActI; CD158J; NKAT-5; CD158 antigen-like family member J; NK receptor 183 ActI; killer-cell ...... |
Chromosomal Location | 19q13.4 alternate reference locus |
External Links | HGNC, NCBI, Ensembl, Uniprot, GeneCards |
Content |
Relations between chemokines (or receptors) and expression, copy number, methylation, or mutation of KIR2DS2. In this tab, users can examine which chemokines (or receptors) might be regulated by the current gene. > Chemokine > Receptor |
Summary | |
---|---|
Symbol | KIR2DS2 |
Name | killer cell immunoglobulin-like receptor, two domains, short cytoplasmic tail, 2 |
Aliases | cl-49; nkat5; 183ActI; CD158J; NKAT-5; CD158 antigen-like family member J; NK receptor 183 ActI; killer-cell ...... |
Chromosomal Location | 19q13.4 alternate reference locus |
External Links | HGNC, NCBI, Ensembl, Uniprot, GeneCards |
Content |
Distribution of KIR2DS2 expression across immune and molecular subtypes. > Immune subtype > Molecular subtype |
Summary | |
---|---|
Symbol | KIR2DS2 |
Name | killer cell immunoglobulin-like receptor, two domains, short cytoplasmic tail, 2 |
Aliases | cl-49; nkat5; 183ActI; CD158J; NKAT-5; CD158 antigen-like family member J; NK receptor 183 ActI; killer-cell ...... |
Chromosomal Location | 19q13.4 alternate reference locus |
External Links | HGNC, NCBI, Ensembl, Uniprot, GeneCards |
Content |
Associations between KIR2DS2 and clinical features. > Overall survival analysis > Cancer stage > Tumor grade |
Summary | |
---|---|
Symbol | KIR2DS2 |
Name | killer cell immunoglobulin-like receptor, two domains, short cytoplasmic tail, 2 |
Aliases | cl-49; nkat5; 183ActI; CD158J; NKAT-5; CD158 antigen-like family member J; NK receptor 183 ActI; killer-cell ...... |
Chromosomal Location | 19q13.4 alternate reference locus |
External Links | HGNC, NCBI, Ensembl, Uniprot, GeneCards |
Content | Drugs targeting KIR2DS2 collected from DrugBank database. |
There is no record. |